This afternoon, Bournemouth officially announced the signing of Leverkusen winger Adley, and it is reported that the total transfer fee is 29 million euros.
According to German statistics, such a price makes Adrie the third most expensive player to sell to pharmaceutical companies this summer, second only to Wilz of 125 million euros and Flynnon of 40 million euros.
Note: The German transfer has not counted the amount of the floating clause of Adria's transfer
At the same time, Leverkusen is also facing the problem of losing most players in the previous winning lineup. However, Tenghach does not seem to need to worry about this: the pharmaceutical factory has earned about 230 million euros by selling players this summer, and currently, buying players (including signing Kanssa, Tillman and others through breaking the team history signing record) has only spent less than 120 million euros.
In other words, the net income of pharmaceutical companies after various operations in the transfer window this summer has now reached more than 100 million euros.
At the moment Adrie has left and forward Bonifas is also close to leaving the team, how to make good use of the remaining more than 100 million euros to maintain good operation and continue to rebuild the roster will be the issue that Leverkusen and coach Ten Hach need to consider.